preclinical model comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Therefore almost all patients will in addition require immunosuppressants, such as prednisone, mycophenolate or azathioprine, as acetylcholinesterase inhibitors alone are insufficient. The surgical removal of the thymus may improve symptoms in certain cases. Plasmapheresis and high-dose intravenous immunoglobulin may be used when oral medications are insufficient to treat severe symptoms, including during sudden flares of the condition. On rare occasions the respiratory muscles can become significantly weak, subsequent mechanical ventilation may then be required. Once intubated, acetylcholinesterase inhibitors may be temporarily withheld to reduce airway secretions. Myasthenia gravis affects 50 to 200 people per million. It is newly diagnosed in 3 to 30 people per million each year. Increased awareness has made diagnosis more common. Myasthenia gravis most commonly occurs in women under the age of 40 and in men over the age of 60. It is uncommon in children. With treatment, most have fulfilling lives and have a normal life expectancy. The word is from the Greek mys, "muscle" and asthenia "weakness", and the Latin gravis, "serious".
General Public were an English new wave band, formed in Birmingham in 1983, by vocalists Dave Wakeling and Ranking Roger of the Beat, and which also included former members of Dexys Midnight Runners, the Specials, and the Clash. They are best remembered for their hits "Tenderness" (1984) and "I'll Take You There" (1994).
By using QDs, only the necessary colors for ideal images are contained in the screen. The first commercial application of quantum dots was the Sony XBR X900A series of flat panel televisions released in 2013. In June 2006, QD Vision announced technical success in making a proof-of-concept quantum dot display and show a bright emission in the visible and near infrared region of the spectrum. A QD-LED integrated at a scanning microscopy tip was used to demonstrate fluorescence near-field scanning optical microscopy (NSOM) imaging.
=== Cardiac disease === Ciclosporin has been used experimentally to treat cardiac hypertrophy (an increase in cell volume). Inappropriate opening of the mitochondrial permeability transition pore (MPTP) manifests in ischemia (blood flow restriction to tissue) and reperfusion injury (damage occurring after ischemia when blood flow returns to tissue), after myocardial infarction (heart attack) and when mutations in mitochondrial DNA polymerase occur. The heart attempts to compensate for disease state by increasing the intracellular Ca2+ to increase the contractility cycling rates. Constitutively high levels of mitochondrial Ca2+ cause inappropriate MPTP opening leading to a decrease in the cardiac range of function, leading to cardiac hypertrophy as an attempt to compensate for the problem. Cyclosporin A has been shown to decrease cardiac hypertrophy by affecting cardiac myocytes in many ways. Cyclosporin A binds to cyclophilin D to block the opening of MPTP, and thus decreases the release of protein cytochrome C, which can cause programmed cell death. CypD is a protein within the MPTP that acts as a gate; binding by cyclosporin A decreases the amount of inappropriate opening of MPTP, which decreases the intramitochondrial Ca2+. Decreasing intramitochondrial Ca2+ allows for reversal of cardiac hypertrophy caused in the original cardiac response. Decreasing the release of cytochrome C caused decreased cell death during injury and disease. Cyclosporin A also inhibits the phosphatase calcineurin pathway (14).
Mambalgin1 binding to hASIC1aΔC induces a conformational change in Finger-II of Mamba1. The significant residues from hASIC1aΔC in this interaction are Asp347, Asp351, and Phe352 on the α5 helix of the thumb domain. These residues interact with Phe27 and Arg28 on Mambalgin1, likely forming salt bridges and causing the hASIC1aΔC residues to flip outward from the acidic pocket. This change is significant as the tip region of Finger-II flips to the thumb domain of hASIC1aΔC to facilitate the interaction between the toxin and the channel.
Sources: en.wikipedia.org
DROME: Gln-Tyr-Met-Ser-Pro-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide APIME: Thr-Met-Ile-Ser-Tyr-Met-Thr-Leu-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide DAPPU: Asp-Ser-Tyr-Leu-Ser-Met-Cys-His-Phe-Lys-Leu-Cys-Asn-Leu-amide
On 4 November 2023, United States Secretary of State Antony Blinken thanked prime minister Najib Mikati during a meeting in Amman "in preventing Lebanon from being pulled into a war that the Lebanese people do not want". U.S. Secretary of Defense Lloyd Austin expressed concern about Israel's role in ongoing tensions with Lebanon. On 30 September 2024, the Pentagon said it would be deploying a "few thousand" more troops to the Middle East. On 1 October 2024, Defense Secretary Austin told Israeli defense minister Yoav Gallant that the United States supports Israel's ground offensive against Hezbollah in southern Lebanon. The U.S. Embassy in Beirut announced on 27 September 2024 that it was "not evacuating U.S. citizens at this time." In response, U.S. Representative Rashida Tlaib stated, the State Department was "leaving Americans behind and failing to protect their own citizens". American citizens in Lebanon stated they were being treated like "lesser US citizens". Lebanese Americans filed a class-action lawsuit against the State Department in the hopes of expediting an evacuation.
== Cited sources == Vandenbosch, Robert & Vandenbosch, Susanne E. (2007). Nuclear waste stalemate. Salt Lake City: University of Utah Press. ISBN 978-0874809039. Hecker, Siegfried S. (2000). "The Plutonium Challenge-Environmental Issues". Los Alamos Science (26). Los Alamos National Laboratory: 36–47. Retrieved 1 October 2023.
=== Insulin glargine/lixisenatide === Insulin glargine/lixisenatide, marketed under the brand name Soliqua, is a fixed-dose combination medication that combines insulin glargine and lixisenatide for the treatment of diabetes. The most common side effects include hypoglycemia, diarrhea, vomiting, and nausea. Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017. It is currently only marketed by Sanofi as Soliqua.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.